Here are five insights:
1. The drug, KCP 400, comes from a cone snail venom protein.
2. The drug does not include venom, however, as Kineta created a synthetic version.
3. Unlike opioids, which target the brain and spinal cord to hide the pain, KCP 400 focuses on the exact injury site to block pain signals.
4. Kineta is planning human clinical trials, where clinicians inject patients with the drug weekly.
5. The company plans to initiate the trials in 2018.
More articles on spine:
Physician Partners of America welcomes Dr. Chad Gorman: 5 insights
Dr. Kadhya David Muballe develops Livingstone Hospital neurosurgery department: 5 points
Erlanger Health adds Drs. Prayash Patel & Megan Stevens: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
